Local pharmaceutical companies are vigorously building production bases, and the pharmaceutical machinery industry may usher in new opportunities

【Pharmaceutical Network Market Analysis】On November 3, Puli Pharmaceutical said on the investor interaction platform that up to now, the company has three production bases, located in Haikou, Hangzhou and Anqing
.
The company hopes to gradually release the production capacity of its various production
sites.
It is understood that the "9-10 lines of Puli International High-end Production Line Expansion Project" in the Haikou production base is planned to start trial production workshop by workshop at the end of 2022, and will gradually reach production
in the later stage.
Local pharmaceutical companies vigorously build production bases, and the pharmaceutical machinery industry ushers in new opportunities (Image source: Pharma.
com) In addition to Puli Pharmaceutical, in fact, many local pharmaceutical companies have also announced the establishment of new R&D and production bases
this year.
For example, Beijing New Leading Pharmaceutical Technology Development Co.
, Ltd.
announced in October that the "New Leading (Chongqing) Biomedical Integration R&D Service Base" project was completed and put into use in Yongchuan District, which is the first biomedical integrated R&D service base project
completed and put into use in Yongchuan.
It is reported that the total investment of the project is 2.
4 billion yuan, the construction content is the research and development and production of small molecule CDMO chemical raw materials and APIs, and will expand small molecule CDMO pharmaceutical preparations, drug research and development, new technology promotion and application and other projects
in the future.
In September, Kelleying announced that the company had signed an investment agreement with the Administrative Committee of Taixing Economic Development Zone in Jiangsu Province on September 26, 2022, and the company intends to invest 4-5 billion yuan in Taixing to invest in the biomedical R&D and production integration base project
。 On August 30, Hualan Biotech said on the investor interaction platform that its pharmaceutical R&D and intelligent production base has started construction; In July, WuXi AppTec and WuXi Biologics both announced that they plan to build a new R&D and production base in Singapore with S$2 billion, or about 9.
9 billion RMB, in the next ten years.
.
.
Industry analysts believe that a large number of enterprises have begun to build R&D production bases, on the one hand, to accelerate industrial upgrading and improve production, distribution and other capabilities; On the other hand, in order to further expand the company's production capacity and improve market competitiveness
.
In the future, in order to continuously meet the improvement of industrial demand, more and more pharmaceutical companies will choose to build and acquire R&D production bases
.
It is worth noting that as more and more enterprises begin to build production bases, the demand for equipment related to pharmaceutical research and development and production will naturally increase
.
Affected by this, the industry expects that the pharmaceutical equipment industry, which is closely related to drug production and pharmaceutical industry, will usher in more new opportunities
.
Pharmaceutical equipment is an indispensable tool and equipment for pharmaceutical production, and is the "heart" and "engine"
of the pharmaceutical industry.
First of all, as pharmaceutical companies continue to expand their production capacity, their demand for energy-efficient pharmaceutical equipment will continue to increase
.
Secondly, the performance, function, and precise control accuracy of pharmaceutical equipment will directly affect the quality of pharmaceuticals, so in order to make pharmaceutical production more efficient and energy-saving, the industry believes that the intelligent, green, energy-efficient pharmaceutical equipment industry will also play an increasingly important role
.
In general, from the current trend of industry development, pharmaceutical companies have become the norm in the industry to expand their production capacity by choosing to build and acquire production
bases.
In the future, if enterprises want to stand out, they will increasingly need large-scale and intelligent production
.
In this context, the pharmaceutical machinery industry is expected to have great prospects and usher in more new opportunities
for development.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.